Andreas Hochhaus, MD, discusses results from a phase I study suggesting asciminib may have superior efficacy to bosutinib in patients with heavily pretreated chronic myeloid leukemia.
Skip Nav Destination
![]()
![]()
Andreas Hochhaus: Asciminib vs. Bosutinib in Chronic Myeloid Leukemia
December 30, 2021
Connect with us:
CURRENT ISSUE
September 2024
